Antineoplastic Agents

Physiologically Based Pharmacokinetic Modeling: Science and Applications

Volumn , Issue , 2005, Pages 297-317

  O'brien, Wendy Pott ^a  

^a US Environmental Protection Agency Region 8   (United States)

Author keywords

1 D arabinofuranosylcytosine; 17 (allylamino) 17 demethoxygeldanamycin; 2' deoxycoformycin; 2 amino 1,3,4 thiadiazole; 5 fluorouracil; Actinomycin D; Adriamycin; Antineoplastic agents; Capecitabine; Cis dichlorodiammine platinum; Melphalan; Methotrexate; Topotecan; Tumor compartment

Indexed keywords

EID: 77950624729     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0471478768.ch11     Document Type: Chapter

References (30)

1. Bischoff, K. B., Dedrick, R. L., and Zaharko, D. S. (1970). Preliminary model for methotrexate pharmacokinetics. J. Pharm. Sci. 59, 149-154.
2. Bischoff, K. B., Dedrick, R. L., Zaharko, D. S., and Longstreth, J. A. (1971). Methotrexate pharmacokinetics. J. Pharm. Sci. 60, 1128-1133.
3. Blesch, K. S., Gieschke, R., Tsukamoto, Y., Reigner, B. G., Burger, H. U., and Steimer, J. L. (2003). Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: The capecitabine experience. Invest. New Drugs 21, 195-223.
4. Chan, K. K., Cohen, J. L., Gross, J. F., Himmelstein, K. J., Bateman, J. R., Tsu-Lee, Y., and Marlis, A. S. (1978). Prediction of adrimycin disposition in cancer patients using a physiologic, pharmacokinetic model. Cancer Treat. Rep. 62, 1161-1171.
5. Collins, J. M., Dedrick, R. L., King, F. G., Speyer, J. L., and Myers, C. E. (1980). Non-linear pharmacokinetic models for 5-fluorouracil in man: Intravenous and intraperitoneal routes. Clin. Pharmacol. Ther. 28, 235-246.
6. Dedrick, R. L., Forrester, D. D., and Ho, D. H. W. (1972). In vitro-in vivo correlation of drug metabolism- Deamination of 1-b-d-arabinofuranosylcytosine. Biochem. Pharmacol. 21, 1-16.
7. Dedrick, R. L., Forrester, D. D., Cannon, J. N., El Dareer, S. M., and Mellett, L. B. (1973a). Pharmacokinentics of 1-b-d-arabinofuranosylcytosine (Ara-C) deamination in several species. Biochem. Pharmacol. 22, 2405-2417.
8. Dedrick, R. L., Zaharko, D. S., and Lutz, R. J. (1973b). Transport and binding of methotrexate in vivo. J. Pharm. Sci. 62, 882-890.
9. Dedrick, R. L., Zaharko, D. S., Lutz, R. J., and Drake, J. C. (1974). Device for controlled drug release- Application to methotrexate infusion in mice. Biochem. Pharmacol. 23, 2457-2461.
10. Dedrick, R. L., Myers, C. E., Bungay, P. M., and DeVita, V. T. (1978). Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. 62, 1-11.
11. Evans, W. E., Crom, W. R., Tsiatis, A., Green, A. A., Hayes, F. A., and Pratt, C. B. (1982). Pharmacokinetic modeling of cisplatin disposition in children and adolescents with cancer. Cancer Chemother. Pharmacol. 10, 22-26.
12. Farris, F. F., King, F. G., Dedrick, R. L., and Litterst, C. L. (1985). Physiological model for the pharmacokinetics of cis-dichlorodiammineplatinum (II) (DDP) in the tumored rat. J. Pharmacokinet. Biopharm. 13, 13-39.
13. Gustafson, D. L., Rastatter, J. C., Colombo, T., and Long, M. E. (2002). Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model. J. Pharm. Sci. 91, 1488-1501.
14. Harris, P. A., and Gross, J. F. (1975). Preliminary pharmacokinetic model for adriamycin (NSC-123-127). Cancer Chemother. Rep. 59, 819-825.
15. King, F. G., and Dedrick, R. L. (1979). Pharmacokinetic model for 2-amino-1,3,4-thiadiazole in mouse, dog, and monkey. Cancer Treat. Rep. 63, 1939-1947.
16. King, F. G., and Dedrick, R. L. (1981). Physiologic model for the pharmacokinetics of 2' deoxycoformycin in normal and leukemic mice. J. Pharmacokinet. Biopharm. 9, 519-534.
17. King, F. G., and Dedrick, R. L. (1992). Physiological pharmacokinetic parameters for cisdichlorodiammineplatinum( II) (DDP) in the mouse. J. Pharmacokinet. Biopharm. 20, 95-99.
18. King, F. G., Dedrick, R. L., and Farris, F. F. (1986). Physiological pharmacokinetic modeling of cisdichlorodiammineplatinum( II) (DDP) in several species. J. Pharmacokinet. Biopharm. 14, 131-154.
19. LeRoy, A. F., Lutz, R. J., Dedrick, R. L., Litterst, C. L., and Guarino, A. M. (1979). Pharmacokinetic study of cis-dichlorodiammineplatinum(II) (DDP) in the beagle dog: Thermodynamic and kinetic behavior of DDP in a biologic milieu. Cancer Treat. Rep. 63, 59-71.
20. Li, J., and Gwilt, P. (2002). The effect of malignant effusions on methotrexate disposition. Cancer Chemother. Pharmacol. 50, 373-382.
21. Lutz, R. J., Dedrick, R. L., Straw, J. A., Hart, M. M., Klubes, P., and Zaharko, D. S. (1975). The kinetics of methotrexate distribution in spontaneous canine lymphosarcoma. J. Pharmacokinet. Biopharm. 3, 77-97.
22. Lutz, R. J., Galbraith, W. M., Dedrick, R. L., Shrage, R., and Mellett, L. B. (1977). A model for the kinetics of distribution of actinomycin-D in the beagle dog. J. Pharmacol. Exp. Ther. 200, 469-478.
23. Sonneveld, P., and Mulder, J. A. (1981). Development and identification of a multicompartment model for the distribution of adriamycin in the rat. J. Pharmacokinet. Biopharm. 9, 577-601.
24. Sung, C., Blaney, S. M., Cole, D. E., Balis, F. M., and Dedrick, R. L. (1994). A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res. 54, 5118-5122.
25. Tsukamoto, Y., Kato, Y., Ura, M., Horii, I., Ishitsuka, H., Kusuhara, H., and Sugiyama, Y. (2001a). A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: The mechanism for tumor-selective accumulation of 5-FU. Pharmacol. Res. 18, 1190-1202.
26. Tsukamoto, Y., Kato, Y., Ura, M., Horii, I., Ishikawa, T., Ishitsuka, H., and Sugiyama, Y. (2001b). Investigation of 5-FU disposition after oral administration of capecitabine, a triple prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: Comparison of the simulated 5-FU exposures in the tumor tissue between human and xenograft model. Biopharm. Drug Dispos. 22, 1-14.
27. Wu, Z.-Y., Smithers, B. M., and Roberts, M. S. (1997). Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb. J. Pharmacol. Exp. Ther. 282, 1131-1138.
28. Xu, L., Eiseman, J. L., Egorin, M. J., and D'Argenio, D. Z. (2003). Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice. J. Pharmacokinetic. Biopharm. 30, 185-218.
29. Zaharko, D. S., Dedrick, R. L., and Oliverio, V. T. (1972). Prediction of the distribution of methotrexate in the sting rays Dasyatidae sabina and sayi by use of a model developed in mice. Comp. Biochem. Physiol. A 42, 183-194.
30. Zaharko, D. S., Dedrick, R. L., Peale, A. L., Drake, J. C., and Lutz, R. J. (1974). Relative toxicity of methotrexate in several tissues of mice bearing Lewis lung carcinoma. J. Pharmacol. Exp. Ther. 189, 585-592.